Home
Clinical Resources Search
PQI: Axitinib (Inlyta®) Plus Pembrolizumab (Keytruda®) for Advanced Renal Cell Carcinoma

Axitinib (Inlyta®) Plus Pembrolizumab (Keytruda®) for Advanced Renal Cell Carcinoma

Download PQI pdf

By: Jennifer Craig, PharmD, CSP | Amber Rollo, PharmD, CSP, AAHIVP

About this PQI

The purpose of this PQI is to provide information on the use of axitinib (Inlyta®) in combination with pembrolizumab (Keytruda ®) in the treatment of advanced renal cell carcinoma, as well as discuss clinical pearls to enhance appropriate patient selection, monitoring, and follow-up.

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care.

Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI